AC Immune SA ( (ACIU) ) has issued an announcement.
AC Immune SA announced its financial results for 2024, highlighting a significant partnership with Takeda for ACI-24.060, which includes an upfront payment of $100 million and potential milestones up to $2.1 billion. The company reported progress in its clinical trials, including positive interim safety data for ACI-7104.056 in Parkinson’s disease and ACI-24.060 in Down syndrome. Additionally, AC Immune received a CHF 24.6 million milestone payment from Janssen for the ACI-35.030 trial, which has been granted Fast Track Designation by the U.S. FDA. These developments underscore AC Immune’s strategic advancements in neurodegenerative disease treatment and its robust financial position, with cash resources expected to fund operations into 2027.
More about AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in precision therapeutics for neurodegenerative diseases. The company focuses on developing active immunotherapies and small molecule programs targeting conditions such as Alzheimer’s and Parkinson’s diseases.
YTD Price Performance: -18.60%
Average Trading Volume: 175,762
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $224.3M
See more insights into ACIU stock on TipRanks’ Stock Analysis page.